School of Pharmacy

Antibody Network partners with Celgene to develop cancer therapies

Tue Sep 15, 2015

James Wells, PhD

A new collaboration between Celgene Corp. and the Recombinant Antibody Network (RAN) will support the development of next-generation, antibody-based cancer therapies.

Bio-artificial Kidney Project Hoping to Raise Funds Through Social Media Crowdfunding Effort

Thu Sep 3, 2015

New Medical Technique Stacks Cells Like Legos

Wed Sep 2, 2015

‘Lego-stacking’ technique could help scientists grow human organs

Wed Sep 2, 2015

Roy receives JDRF funding to develop implants to treat type 1 diabetes

Tue Sep 1, 2015

Silicon nanopore membranes developed in the Roy Lab will provide material to encapsulate pancreatic islets.

UCSF School of Pharmacy faculty member Shuvo Roy, PhD, has received a three-year $1 million grant to create surgically implantable capsules of donor pancreas cells to free type 1 diabetes patients from daily insulin injections and the disease’s potentially life-threatening complications.

Jacobson named chair of the Department of Pharmaceutical Chemistry

Wed Aug 12, 2015

Elisabeth Fall

Matt Jacobson, PhD

Renowned researcher and educator Matthew Jacobson, PhD, has been named the new chair of the UCSF School of Pharmacy’s Department of Pharmaceutical Chemistry. His appointment by Dean B. Joseph Guglielmo, PharmD, will be effective January 15, 2016.

Kroetz leads new study of genetics of cancer drugs’ dose-limiting side effects

Mon Jul 27, 2015

Deanna Kroetz, PhD

Taxanes are a class of drugs widely used to treat a variety of cancers, including breast, ovarian, lung, gastric, and head and neck. But dosages are often limited by toxic side effects—most commonly damage to the body’s peripheral nerves, causing numbness, pain, and/or hyper-sensitivity—that can...

Study discovers why leading gout medication is ineffective for many

Tue Jul 14, 2015

Bobjgalindo

, CC BY-SA 3.0

, GFDL

Spiked rods of uric acid crystals from synovial fluid photographed under a microscope with polarized light. In patients with gout, such crystals can accumulate in the joints, causing pain and inflammation.

Allopurinol, the first-choice medication for treating gout—an excruciatingly painful condition that is the most common form of inflammatory arthritis, afflicts more than eight million Americans, and is on the rise worldwide—is not fully effective in more than half of patients.

California’s SB 493 implementation:  Three, two, one … blast-off!

Wed Jul 8, 2015

Sali named associate dean of research

Tue Jun 30, 2015

Andrej Sali, PhD

Andrej Sali, PhD, has been appointed associate dean of research of the UCSF School of Pharmacy, effective July 1, 2015. The appointment is in addition to Sali’s full professorship in the School’s Department of Bioengineering and Therapeutic Sciences.

School of Pharmacy

Pages